Sperm Count Improvements Linked to GLP-1 Receptor Agonists
New research presented at the AUA 2025 Annual Meeting suggests that GLP-1 receptor agonists — the medications behind Ozempic and Mounjaro — may significantly improve sperm count and overall fertility in overweight and obese men.
An Unexpected Benefit of Weight-Loss Medications
The rise of GLP-1 receptor agonists — medications like semaglutide and tirzepatide, commonly known by brand names such as Ozempic and Mounjaro — has fundamentally changed the treatment of obesity and Type 2 diabetes. However, new research presented at the American Urological Association (AUA) 2025 Annual Meeting suggests these medications may have a significant secondary benefit: improving sperm count and overall fertility in overweight and obese men.
Led by Dr. Skyler Howell of the University of Texas, a retrospective cohort study analysed data from over 3,600 men. The study compared men using GLP-1 receptor agonists for weight management against a control group of men with similar Body Mass Indices (BMI) who were not on the medication. The findings showed that men in the GLP-1 group were significantly more likely to see their sperm counts normalise over the course of the study, with a measurable percentage achieving normal sperm concentration levels — whereas the control group showed stagnant or declining fertility markers.
The Mechanism of Action
Obesity is a well-known driver of male infertility. Adipose (fat) tissue contains the enzyme aromatase, which converts testosterone into oestrogen. This hormonal imbalance can suppress the production of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), which are essential for sperm production. Additionally, chronic inflammation and oxidative stress associated with obesity can cause direct damage to sperm DNA.
The study suggests that GLP-1 receptor agonists work through two primary channels to improve male reproductive health. First, by facilitating significant weight loss and improving insulin sensitivity, these drugs help restore the natural hormonal balance — lowering oestrogen and allowing testosterone levels to recover. Second, GLP-1 receptors have been identified within the Sertoli and Leydig cells of the testes, suggesting the medication may have a direct, non-weight-dependent influence on the microenvironment where sperm are produced.
Clinical Implications
While the study found improvements in sperm concentration and total count, it did not observe a significant change in sperm motility. Dr. Howell cautioned that while these drugs are not fertility medications for every man, they could serve as a vital fertility-sparing intervention.
This is particularly important because many men with obesity-related low testosterone are prescribed Testosterone Replacement Therapy (TRT), which can actually shut down sperm production entirely. GLP-1 receptor agonists may offer a way to improve both metabolic and reproductive health simultaneously, providing a more holistic approach to men's sexual wellness.
More from Pendex
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health concerns.